September 2018

Endocyte Completes $201.3 Million Public Offering

Endocyte, Inc., a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, completed a $201.3 million public offering of common stock. Faegre Baker Daniels advised Endocyte on the transaction. Endocyte's shares trade on the NASDAQ Global Market under the symbol "ECYT."

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。